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The immune system is strongly implicated in the pathophysiology of multiple sclerosis 
(MS), as demonstrated by the efficacy of therapies targeting various components of 
adaptive immunity. However, the disease still progresses despite these treatments in 
many patients, while others experience life-threatening adverse effects, urging for the 
discovery of new immune-targeting medications. Among the immune cell types par-
ticipating to MS pathogenesis, decades of work have highlighted the prominent role of 
CD4 T cells. More recent data demonstrate the involvement of CD8 T cells as well. The 
existence of both pathogenic and protective CD8 T cells subsets has been suggested, 
adding an additional layer of complexity to the picture. Mucosal-associated invariant T 
(MAIT) cells are innate-like lymphocytes that make up to 25% of CD8 T cells in healthy 
subjects. They are specific for conserved microbial ligands and may constitute an 
important barrier against invasive bacterial and fungal infection. An increasing number of 
reports also suggest their possible involvement in chronic inflammatory diseases, includ-
ing MS. MAIT cells could participate through their ability to produce IFNγ and/or IL-17, 
two major cytokines in the pathogenesis of several chronic inflammatory/autoimmune 
diseases. However, the mechanisms by which MAIT cells could be activated in these 
sterile conditions are not known. Furthermore, contradictory observations have been 
made, reporting either a protective or a pro-inflammatory behavior of MAIT cells in MS 
or its murine model, experimental autoimmune encephalomyelitis. In this review article, 
we will describe the current knowledge on MAIT cell biology in health and disease, and 
discuss the possible mechanisms behind their role in MS. The specific features of this 
new non-conventional T cell subset make it an interesting candidate as a biomarker or 
as the target of immune-mediated intervention.
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Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system (CNS). 
MS is characterized by discrete white matter lesions in the brain and spinal cord. The cellular injury is 
primarily oligodendrocytes but MS also affects axons/neurons. This neural demise results in the pro-
gressive neurological disability affecting people with MS. The genetic factors providing susceptibility 
to the disease have been largely deciphered in recent years (1). Polymorphisms at more than 150 loci 
contribute to MS susceptibility. Importantly, the incriminated genes collectively point to a central 
role of the immune system in disease pathogenesis (2, 3). The most studied and also the strong-
est MS-susceptibility genes reside within the human leukocyte antigen (HLA) locus with a major 
September 2015 | Volume 6 | Article 5032
Treiner and Liblau MAIT cells in multiple sclerosis
Frontiers in Immunology | www.frontiersin.org
influence of the DRB1*15:01-HLA-DRB5*01:01-DQB1*06:02 
haplotype and significant impact of HLA class I alleles (4).
There is little doubt that multiple immune cell populations 
are implicated both at the initiation of the disease process and at 
the effector phase responsible for CNS tissue damage. However, 
the respective contribution of these various populations at the 
different phases of the disease remains only partly understood 
(5). Nevertheless, deciphering how the various CD4 and CD8 T 
cell subsets promote and regulate MS immunopathogenesis has 
benefited from progress in fundamental immunology and from 
experimental models (6–8). Much has been learned lately regard-
ing the different functional subsets of CD4 T cells and regarding 
the pathogenic and regulatory influence of CD8 T cells. This has, 
in part, led to new therapeutic directions for the benefit of people 
with MS (9). However, newly identified innate-like T cell popula-
tions, such as innate lymphoid cells, invariant natural killer T 
(iNKT) cells, and mucosal-associated invariant T (MAIT) cells, 
have emerged as important actors in inflammatory diseases. They 
are positioned at the interface between the environment and the 
host and may, therefore, represent a key link for the amplifica-
tion of an immune reaction against microbes. Understanding 
their exact contribution to pathogenesis will undoubtedly open 
innovative therapeutic possibilities.
Here, we review the current knowledge regarding the biology 
of MAIT cells and their possible involvement in MS. Future 
directions are suggested to better apprehend their precise role 
and their usefulness as therapeutic targets.
Mucosal-Associated invariant T Cells: A 
New innate-Like T Cell Subset
Mucosal-associated invariant T cells are a homogenous T cell 
subset displaying features of innate-like T cells, such as γδ or 
iNKT cells. Originally described in humans, they are phyloge-
netically conserved in distant mammal species, including mice 
(10–14). However, the frequency of MAIT cells in laboratory 
mouse strains is low, and there is evidence that they may be 
developmentally and/or functionally different from their human 
counterparts (15). These differences must be kept in mind when 
interpreting results obtained in mice. MAIT cells are mainly 
characterized by a highly restricted TCR repertoire, selected for 
by a monomorphic major histocompatibility complex (MHC) 
class I-like molecule known as MHC-related 1 (MR1) (10). 
Indeed, the vast majority of MAIT cells express an invariant 
TCRα chain (Vα7.2-Jα33 in humans and the homologous 
Vα19-Jα33 in mice) (13, 16). The second important feature of 
MAIT cells is their peripheral maturation/differentiation status; 
in one study, >90% of MAIT cells displayed an effector/memory 
phenotype in healthy adults (17). The ontogeny of MAIT cells in 
mice is dependent upon microbial colonization of the intestine 
soon after birth, suggesting that shared commensal bacterial 
antigens presented by MR1 drive the proliferation and matura-
tion of memory MAIT cells (17). In humans, cord blood harbors 
a small population of naïve MAIT cells that apparently expand 
in early childhood, and differentiate into memory cells (17, 
18), suggesting a similar mechanism of antigen-driven expan-
sion after birth. Seminal studies performed by the Rossjohn 
and McCluskey laboratories led to the discovery of microbial 
antigens for MAIT cells (19, 20). These antigens are low molecu-
lar weight molecules derived from the intermediates of the 
riboflavin (vitamin B2) metabolism. The mammalian genome 
is devoid of the genes necessary to the synthesis of riboflavin; 
however, an important number of different bacterial and fungal 
species are riboflavin producers, and therefore, MAIT cell 
activators (21). It is, therefore, speculated that MAIT cells exit 
the thymus as naïve cells, and then encounter bacterial antigens 
(probably originating from the commensal flora), driving their 
early maturation in the periphery. However, a recent study 
challenged this hypothesis, showing evidences of MAIT cell 
proliferation and differentiation in the peripheral organs of sec-
ond trimester human fetuses (22) This would suggest that MAIT 
cells can mature before bacterial colonization of the body with 
commensal microbes, and has profound consequences on our 
understanding of MAIT cells reactivity toward various cognate 
ligands and/or environmental cues; more studies are, there-
fore, needed to unravel these processes. Activation of MAIT 
cells leads to cytokine secretion, mostly interferon γ (IFNγ) 
and tumor necrosis factor α (TNFα), as well as induction of 
degranulation and cytotoxicity (23–25). Virtually all MAIT cells 
in humans express high levels of CD161, as well as the IL-23 
receptor (IL-23R), the C-C chemokine receptor 6 (CCR6) and 
the transcription factor RAR-related orphan receptor gamma 
t (RORC2/RORγt), three markers associated with interleukin 
17 (IL-17) producing subsets (Figure  1) (16, 18, 23). Indeed, 
IL-17-secreting MAIT cells can be found in some settings, 
mostly in pathological conditions (see below) (23, 26–31). The 
phenotype of MAIT cells in wild-type mice has been described 
recently (Figure 1). In peripheral tissues, such as the lung, they 
uniformly express a memory phenotype (CD44hiCD62Llo), the 
FiGURe 1 | Phenotype of human and mouse MAiT cells. Blood MAIT 
cells in humans are defined as TCRVα7.2+CD161hi-expressing T cells. Most 
MAIT cells are CD8+, and express an effector/memory phenotype 
CD45RO+CD62LloCCR7− (not depicted). They express several chemokine- 
and interleukin-receptors at steady state. They are equipped with the 
cytotoxicity co-receptor NKG2D, and display intra-cytoplasmic granules 
containing granulysin, granzyme B, and perforin. The expression of CD161, 
IL-18Rα, or CD26 at high levels is usually sufficient to identify MAIT cells 
within the CD8+ subset in human blood. The phenotype of mouse MAIT cells 
is apparently more diverse, and dependent upon the tissues examined. Most 
of them are CD4−CD8− (double negative), display an effector/memory 
phenotype and the interleukin and chemokine receptors IL-7Rα, IL-18Rα, 
and CXCR6 (16, 17, 23, 24, 32).
FiGURe 2 | MAiT cell interactions with MR1+ antigen-presenting cells. 
The semi-invariant TCR of MAIT cells allows recognition of a complex made 
of MR1 associated with a bacterial-derived riboflavin derivative. MR1-
dependent interactions with MAIT cells has been formerly demonstrated with 
professional antigen-presenting cells (APCs), such as monocytes, 
macrophages, dendritic cells, and B cells as well as with epithelial cells. 
Professional APCs may influence MAIT cell response through secretion of 
IL-12 and IL-18, and by providing co-stimulation. MAIT cell effector functions 
primarily involve IFNγ secretion and degranulation of their cytotoxic content, 
thereby inducing killing of infected epithelial cells.
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cytokine receptors IL-7R and IL18R, and the C-X-C chemokine 
Receptor 6 (CXCR6) chemokine receptor, akin to humans (32). 
Other surface markers show a more diverse pattern of expres-
sion, suggesting that mouse MAIT cells may be more diverse 
than their human counterparts. In particular, most mouse 
MAIT cells lack both CD4 and CD8, but variable proportions of 
CD4 and CD8 cells are found in a tissue-specific fashion (32). In 
agreement with their anti-microbial reactivity, MAIT cells react 
against a wide array of bacteria in vitro, by producing IFNγ and 
lysing bacteria-infected cells (19, 24, 25, 33–36). In vitro analysis 
showed that their functional response is regulated by several 
cytokines, such as IL-7, IL-12, IL-18, and IL-23 (Figure 2) (26, 
30, 37, 38). MAIT cells may be particularly involved in the 
immune response against Mycobacterium tuberculosis: patients 
with active tuberculosis show a depleted blood MAIT cell 
compartment resulting from their recruitment to the lung (33, 
38–40). All evidence points out an important role for MAIT 
cells as a first line of defense against invasive bacterial infec-
tions, chiefly at mucosal surfaces (41).
An increasing number of studies have reported the likely 
involvement of MAIT cells in non-bacterial diseases. These 
include chronic viral infections like human immunodeficiency 
virus (HIV) (42–48), autoimmune diseases [such as inflamma-
tory bowel diseases (IBD), systemic lupus erythematosus (SLE), 
MS, or psoriasis] (27, 31, 49–52), other inflammatory or hyper-
sensitivity diseases, and even cancer (28, 29, 53–56). Although 
the significance of these observations is still unknown, they point 
out a possible role for MAIT cells in the pathogenesis of many 
inflammatory conditions.
MAiT Cells in MS and eAe
The first study focusing on MAIT cells in the context of CNS 
inflammation was performed in humans. Because at the time 
there was no tool available to directly identify MAIT cells (such as 
TCR-targeting antibodies or tetramers), the transcripts encoding 
the MAIT cell-specific invariant TCRα chain Vα7.2-Jα33 were 
searched for within the CNS (49). An accumulation of such 
mRNA species was found in autopsy lesions from MS patients 
in 50% of the analyzed cases, as well as in 73% of cerebrospinal 
fluid samples obtained from patients experiencing relapses. The 
authors concluded that MAIT cells are involved in the CNS 
inflammation. The same group further investigated the role of 
MAIT cells in the EAE mouse model. As MAIT cells are scarce in 
mice, they increased their number and frequency by generating 
a mouse transgenic (Tg) for the MAIT cell-specific TCRα chain 
(iVα19). Upon immunization with a myelin oligodendrocyte 
glycoprotein (MOG) peptide (57), iVα19 Tg mice showed 
dramatically reduced EAE incidence and severity, as compared 
with wild-type B6 or CD1d-deficient mice, which lack CD1d-
restricted iNKT cells. A similar regulatory effect of MAIT cells 
was observed in regular B6 mice adoptively transferred with 
iVα19 Tg cells, as well as in MR1 knock-out (KO) mice compared 
to wild-type animals. iVα19 Tg cells induced IL-10 production by 
B cells in a MR1-independent manner in vitro, accompanied by a 
reduction in the production of inflammatory cytokines by MOG-
specific T cells, probably accounting for the EAE-protecting effect 
of MAIT cells. Altogether, these data strongly suggested that 
MAIT cells display an immune-regulatory function in the context 
of EAE. The interpretation of these data was, however, hampered 
by the fact that iVα19 Tg mice were not crossed onto a Cα KO 
background, thereby allowing endogenous TCRα chains to be 
recombined and expressed. It is, therefore, difficult to evaluate 
how the alterations induced in the TCR repertoire of iVα19 Tg 
mice could have impacted the data obtained in the EAE model.
However, this striking paper triggered several studies evalu-
ating MAIT cell numbers and functions in MS patients, which 
yielded contradictory results. Miyazaki et al. observed a dramatic 
reduction in the frequency of blood MAIT cells in patients 
with relapsing-remitting MS (RR-MS) (58). The frequency of 
blood MAIT cells inversely correlated with disease activity as 
it was lower in active disease as compared to stable patients. 
Interestingly, steroid treatment of active patients induced a rise 
in the frequency of MAIT cells. This may suggest that a revers-
ible, altered distribution could be responsible for their depletion 
from blood in the acute phases of inflammation. It was suggested 
from in vitro experiments that MAIT cells suppress IFNγ pro-
duction by other T cell subsets, akin to the data obtained with 
iVα19 Tg mice; however, this suppression was independent of B 
cells or IL-10 production. By contrast, Annibali et al. observed 
an increased frequency of CD8+CD161hi T cells in the blood of 
MS patients (51). Several independent studies have clearly dem-
onstrated that this T cell subset is almost exclusively composed 
of MAIT cells (16, 18). CD8+CD161hi T cells from MS patients 
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displayed an inflammatory phenotype characterized by high 
IL-17 production, and could be found in post-mortem brain 
biopsies within perivascular cuffs and chronic active lesions. 
Thus, MAIT cells in these patients behaved oppositely from the 
previous reports, and suggested a pro-inflammatory pathogenic 
role in MS. These data were in part corroborated by an analysis 
of post-autologous hematopoietic stem cell transplantation in MS 
patients. This study showed that MAIT cells were depleted by a 
conditioning regimen including cyclophosphamide or alemtu-
zumab and did not recover for more than 2 years post-graft (59). 
Before immunosuppressive conditioning, the patients exhibited a 
high frequency of MAIT cells, together with a pro-inflammatory 
profile. Moreover, MAIT cells were identified within white mat-
ter inflammatory lesions from post-mortem samples of nine MS 
cases. In addition, a recent report described a significant but 
modest decrease of MAIT cells in the blood of RR-MS patients 
(60), and confirmed their presence in brain lesions. Stimulation 
of MAIT cells with IL-18 induced very late antigen 4 (VLA-4) 
up-regulation, providing a possible mechanism to explain their 
migratory behavior. In agreement with this, the decrease in blood 
MAIT cells was inversely correlated with IL-18 plasma levels (60). 
More recently, Held and collaborators made a strong effort to 
identify antigen-driven T cells expansion within brain lesions by 
combining laser microdissection and TCR pyrosequencing (61). 
They indeed observed massive expansion of T cell clones that 
persisted for several years. Surprisingly, TCRs closely related to, 
but distinct from, the MAIT cells’ TCR were found, whereas the 
canonical TCR Vα7.2-Jα33 was present as a minor fraction (61). 
It is not clear at this point to what extent these TCRs allow any 
recognition of MR1, and how T cells expressing these specifici-
ties are indeed related to MAIT cells. Thus, opposite results are 
described with regard to MAIT cell frequency and functions in 
MS patients, and the reasons underlying these discrepancies are 
currently not clear. It should be pointed out at this point that 
the effect of immunosuppressive/immunomodulatory regimen 
on MAIT cells has never been studied, with the exception of 
the hematopoietic stem cell transplantation study mentioned 
above. The cohorts analyzed in these various articles included 
patients that were free of any current medication affecting the 
immune system, but no mention of previous treatments was 
made, with the exception of the Annibali’s work, which analyzed 
mostly treatment-naïve patients. Therefore, differences in treat-
ment history may hamper a valid comparison of these cohorts. 
Nevertheless, available data suggest that MAIT cells in MS gain 
the ability to traffic to the CNS, which in some cases may explain 
their depletion from blood, as seen in other pathological settings 
(see below).
MAiT Cells in Other Autoimmune/
inflammatory Diseases
Several reports have described alterations in the frequency, phe-
notype, location and/or functions of MAIT cells in inflammatory 
diseases, mostly in human samples and sometimes in mouse 
models. Most studies found a decreased frequency of blood 
MAIT cells, in patients with SLE, celiac disease, or IBD (31, 52, 
56). When studied, the function of MAIT cells was altered, with 
decreased IFNγ production in SLE and IBD, and increased IL-17 
secretion in IBD. Increased MAIT cell frequency was found in 
the inflamed intestinal tissue of IBD patients as well as in skin 
lesions of patients with psoriasis (27, 31). MAIT cells appeared 
pathogenic in a mouse model of autoimmune arthritis (62). In 
this study, the authors showed that MR1 KO animals were less 
sensitive to both active (collagen-induced) and passive (antibody-
induced) arthritis than wild-type animals. Moreover, they used 
adoptive transfer of MAIT cells from iVα19 Tg mice (with the 
limitations already described) to reveal the disease-enhancing 
role of MAIT cells in the passive arthritis model. Recently, two 
seminal studies documented the behavior of MAIT cells in obese 
patients. It appears that, similar to several autoimmune or infec-
tious diseases, MAIT cell frequency gradually declines in the 
blood of obese patients, and increases in the adipose tissue where 
MAIT cells are prone to produce IL-17 (28, 29).
Putative Mechanisms of MAiT Cells 
involvement in MS and Other 
inflammatory Diseases
The diverse and clonal expression of the TCR by T cells implies 
that different clones react against different ligands. MAIT cells 
display very limited repertoire diversity and therefore should 
recognize a limited set of different ligands. However, akin to other 
innate T cell subsets (such as γδ T cells or CD1d-restricted iNKT 
cells), the antigens recognized by MAIT cells are highly conserved 
and potentially expressed by a large variety of bacteria and fungi 
(34). This property accounts for the activation of MAIT cells by 
various microorganisms, such as Escherichia coli, Mycobacterium 
tuberculosis, Klebsiella pneumoniae, Shigella flexnerii, Salmonella 
typhimurium, Vibrio cholerae, or Francisella tularensis, and cer-
tainly many others (20, 24, 33–35, 63–66).
However, our knowledge of the mechanisms by which MAIT 
cells are recruited and activated in non-infectious inflammatory 
diseases is minimal. The first general hypothesis postulates that 
MAIT cells are activated in a cognate manner, by recognition of 
their specific Ags. But what would be the origin of these antigens? 
In the case of intestinal inflammatory diseases, alterations in the 
permeability of the gut epithelial barrier and subsequent translo-
cation of microbial products may promote MAIT cell activation. 
Further, recent findings suggest that this general mechanism 
is involved in the pathogenesis of non-intestinal inflammatory 
diseases, including MS (67, 68). However, it would be difficult 
to explain how a low level of microbial translocation would 
induce a strong MAIT cell activation, given the fact that their 
specific ligands appear to be extremely unstable (20), which could 
actually be a regulation mechanism. Alternatively, there may be 
endogenous ligands for MAIT cells, whose expression could be 
induced and/or increased in the context of inflammation. It must 
be pointed out that there is to date no demonstration that such 
endogenous ligands exist. However, this could be inferred from 
several studies analyzing MAIT cell ontogeny, which proved that 
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MAIT cells are positively selected on hematopoietic cells in the 
thymus in the presence of MR1 only (10, 69). Thus, although it 
is highly probable that such endogenous ligands for MAIT cells 
exist, their molecular characterization is still eagerly awaited.
The second hypothesis to explain such broad involvement 
of MAIT cells in inflammatory diseases involves a bystander 
mechanism, i.e., in the absence of their antigen recognition 
through their TCR. MAIT cells are effector/memory cells, and 
as such, are equipped with a panel of receptors involved in cell 
migration, or in the response to inflammatory mediators [Toll-
like receptors (TLR), cytokine receptors, etc.]. Notably, MAIT 
cells can be activated to produce IFNγ in the mere presence 
of cytokines, specifically a combination of IL-12 and IL-18 
(37). Jo et al. showed that the TLR7/8 agonist R848 stimulates 
monocytes to produce IL-12 and IL-18, which in turn activate 
IFNγ secretion by MAIT cells (70). Further, bacteria devoid of 
MR1-binding ligands, such as Streptococcus pneumoniae, also 
induce the production of these cytokines by antigen-presenting 
cell (APC) and subsequent MAIT cell activation. IL-12 is 
involved in many autoimmune diseases, including MS (and 
EAE); IL-18 is also a major cytokine whose role in driving auto-
immune diseases but also hypersensitivity conditions is gaining 
strong interest (71, 72). Therefore, it could be proposed that 
the inflammatory milieu drives MAIT cell activation through 
cytokine responsiveness, leading to their recruitment in the 
inflamed lesions of the brain in MS. Indeed, IL-18 apparently 
up-regulates VLA-4 at the surface of MAIT cells, providing a 
molecular clue as to how the cytokine milieu might influence 
MAIT cells migratory behavior (60). Other cytokines, such as 
IL-1β, which shares with IL-18 an inflammasome-dependent 
processing, might also be involved.
Possible Roles of MAiT Cells in the 
inflamed Brain During MS
Mucosal-associated invariant T cells can be found in the inflamed 
CNS lesions from MS patients; they are also observed in other 
inflamed tissues, such as the skin of psoriatic patients. This raises 
the obvious question of their functions within tissues and their 
relevance to the pathogenesis of these diseases in general. Very 
little information is available about MAIT cell functions in tis-
sues, and we are currently led to speculate on this matter. It is 
of course possible that they are only innocent bystanders in the 
inflammatory lesions and do not play any important role. Blood 
MAIT cells are equipped with receptors involved in migration 
to the CNS, such as CCR5 (in the steady-state) and VLA-4 (after 
stimulation). Indeed, MAIT cells are usually identified in low 
frequency within target tissues of inflammation. On the other 
hand, it must be reminded that MAIT cells are effector/memory 
cells prone to produce inflammatory cytokines and to release 
cytotoxic granules. Several reports showed that circulating blood 
MAIT cells in diseases, such as IBD, type 2 diabetes (T2D), and 
MS, display increased cytokine-producing functions, in par-
ticular IL-17, as compared with their counterparts from healthy 
donors (29, 31, 51). Therefore, infiltrating MAIT cells in MS are 
functionally active, which may suggest their involvement in the 
disease. If so, the next question is: what role do MAIT cells play 
in the inflamed brain?
Upon activation, cytokine secretion by MAIT cells is mostly 
related to a Tc1/Tc17 pattern, i.e., IFNγ and/or IL-17 as well 
as GM-CSF and TNFα. All these cytokines are considered as 
major culprits in many autoimmune diseases, including MS. 
From there, it is tempting to speculate that MAIT cells are 
pro-inflammatory cells with deleterious effects in the disease 
process. Furthermore, given that MAIT cells are cytotoxic 
against bacteria-infected epithelial cells, it is possible that in 
MS they gain the ability to kill oligodendrocytes, axons/neu-
rons, or even other CNS-resident cell types. Direct evidence 
supporting this hypothesis is, however, lacking. Although 
MR1 (the restriction molecule for MAIT cells) appears to be 
broadly expressed, its expression in CNS cells has never been 
investigated. This aspect needs to be addressed in MS as well as 
in other CNS inflammatory diseases. We think that the current 
knowledge regarding the functional properties of MAIT cells 
does not permit to predict whether these cells ultimately play 
a pro-inflammatory or regulatory role in MS. MS is probably a 
heterogeneous disease with regard to the precise mechanisms 
of pathogenesis. Although the issue is not totally resolved, there 
is increasing evidence that both inflammasome-dependent and 
inflammasome-independent mechanisms exist that would be 
differentially elicited in patients, and that this may underlie the 
differential response to therapy (73, 74). We postulate that this 
heterogeneity in the disease pathogenesis could partially explain 
the contradictory results found by different teams with regard 
to the pro-inflammatory or regulatory role of MAIT cells in MS 
and EAE. If this hypothesis holds true, we also anticipate that 
there could be a correlation between MAIT cells functions in 
MS (for instance, IFNγ versus IL-17 production) and response 
to disease-modifying therapies, suggesting a possible use as an 
immunological biomarker.
Concluding Remarks
The multifaceted nature of MAIT cells makes them promising 
candidates for therapeutic targeting and/or to use as biomarker 
of disease. A strong body of work strongly suggests that MAIT 
cells are involved in MS, fostering new studies aiming at deci-
phering their precise role in pathogenesis. Studies in human 
patients are obviously hampered by the limited access to tissue 
samples. One interesting avenue would be to analyze MAIT 
cells phenotype and functions in patients stratified according 
to their response to therapy. Limitations of the murine models 
available thus far have been already described. However, a 
report published while this review was in preparation described 
MAIT cells in wild-type mice, with the help of MR1 tetramers 
(32). The authors suggest that mouse MAIT cells more closely 
resemble their human counterparts than previously thought, 
although important differences remain, such as a much lower 
frequency and a more pronounced Tc17 skewing of cytokine 
secretion. There is no doubt that future analysis of MAIT cells 
in the EAE model will yield relevant data as to their role in this 
disease.
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